Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.
But whether data on the novel anaemia pill are clean enough to dispel wider FDA toxicity concerns is hard to call.
A strong performance from a handful of large drug developers could not rescue the sector from a weak three months on the stock market.
But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.